The news roundup from the ASH 2024 conference includes a feud between biotech companies Arcellx and Legend Biotech over their CAR-T therapies for multiple myeloma. Arcellx received a waiver to highlight the safety of their treatment, while Legend remains confident in their market presence. Additionally, a study suggests that stem cell transplants may not be necessary for mantle cell lymphoma patients in deep remission. In pediatric acute lymphoblastic leukemia, Amgen’s Blincyto improves disease-free survival, especially in Hispanic children. Abbvie’s Epkinly shows promise for CLL patients who have relapsed or are refractory, offering a chance for a complete remission.
Source link
ASH 2024: Roundup of news from last day of hematology meeting
